The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Hospital Corporation of America
Honoraria - Bicycle Therapeutics; Guardant Health; Roche
Consulting or Advisory Role - Bicycle Therapeutics; Guardant Health; Roche
Research Funding - TBD (Inst)
A phase I/II first-in-human trial of oral SRA737 (a Chk1 inhibitor) given in combination with low-dose gemcitabine in subjects with advanced cancer.
 
Udai Banerji
Employment - Institute of Cancer Research
Honoraria - Astellas Pharma; Lilly
Consulting or Advisory Role - Novartis; Phoenix Solutions
Research Funding - AstraZeneca (Inst); BTG (Inst); Chugai Pharma (Inst); Onyx (Inst); Verastem (Inst)
Travel, Accommodations, Expenses - Sierra Oncology
 
Elizabeth Ruth Plummer
Honoraria - Amgen (I); Bristol-Myers Squibb; Pfizer (I); Roche/Genentech
Consulting or Advisory Role - Astex Pharmaceuticals; Bayer; Biosceptre; Clovis Oncology; Cybrexa Therapeutics; Ellipses Pharma; Karus Therapeutics; MSD Oncology; Novartis; Octimet; Pierre Fabre; Roche/Genentech
Speakers' Bureau - Novartis
Research Funding - AstraZeneca/MedImmune (Inst)
Patents, Royalties, Other Intellectual Property - Named on patent of use of PARP inhibitor rucaparib (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD Oncology
 
Victor Moreno
Employment - START
Consulting or Advisory Role - Merck
Research Funding - Abbvie (Inst); ACEA Biosciences (Inst); Adaptimmune (Inst); Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); E-therapeutics (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Menarini (Inst); Merck (Inst); Nanobiotix (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); PsiOxus Therapeutics (Inst); Puma Biotechnology (Inst); Regeneron (Inst); RigonTEC (Inst); Roche (Inst); Sanofi (Inst); Sierra Oncology (Inst); Synthon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tesaro (Inst); Transgene (Inst)
Expert Testimony - Medscape/Bayer; Nanobiotix
Travel, Accommodations, Expenses - Sanofi/Regeneron
 
Joo Ern Ang
No Relationships to Disclose
 
Amy Quinton
No Relationships to Disclose
 
Yvette Drew
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Clovis Oncology
Speakers' Bureau - AstraZeneca
Research Funding - Clovis Oncology (Inst); Verastem (Inst)
Travel, Accommodations, Expenses - Clovis Oncology
 
Tatiana Hernández
No Relationships to Disclose
 
Desamparados Roda
No Relationships to Disclose
 
Louise Carter
Consulting or Advisory Role - Athenex; Bicycle Therapeutics
Research Funding - Athenex (Inst); Bristol-Myers Squibb (Inst); Sierra Oncology (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Athenex; BerGenBio; BerGenBio
 
Alejandro Navarro
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; Pfizer; Roche
Expert Testimony - Oryzon Genomics
Travel, Accommodations, Expenses - Boehringer Ingelheim; Pfizer
 
Rebecca Sophie Kristeleit
Honoraria - AstraZeneca; Clovis Oncology; Roche/Genentech; Tesaro
Consulting or Advisory Role - Basilea; Cerulean Pharma; Clovis Oncology; Roche/Genentech; Sotio
Travel, Accommodations, Expenses - Basilea; Clovis Oncology; Valirx
 
Hendrik-Tobias Arkenau
No Relationships to Disclose
 
Debashis Sarker
Honoraria - Bayer; Ipsen; Pfizer; Pfizer (I)
Consulting or Advisory Role - Eisai; Eisai (I); Ipsen (I); Novartis
Travel, Accommodations, Expenses - Bayer; ipsen; MiNA Therapeutics
 
Daniel E. Castellano
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Ipsen; Janssen Oncology; Lilly; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Sanofi; Sanofi
Research Funding - Janssen Oncology (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Pfizer; Roche
 
Harriet Walter
Honoraria - Abbvie
Travel, Accommodations, Expenses - Abbvie; Gilead Sciences
 
Patricia Roxburgh
Research Funding - AstraZeneca (Inst); Athenex (Inst); Clovis Oncology (Inst); FORMA Therapeutics (Inst); Immutep (Inst); Iovance Biotherapeutics (Inst); Nucana (Inst); PsiOxus Therapeutics (Inst); Replimune (Inst); Sierra Oncology (Inst); Tesaro (Inst)
 
Sarah Patricia Blagden
Stock and Other Ownership Interests - RNA Guardian; RNA Guardian (I)
Speakers' Bureau - Clovis Oncology; OCTIMET
Research Funding - Incyte (Inst); Nucana (Inst); octimet (Inst); Piqur (Inst); Redx Pharma (Inst); Sierra Pharma (Inst); Tesaro (Inst)
Patents, Royalties, Other Intellectual Property - WO 2016075455 A1 circulating LARP1
Travel, Accommodations, Expenses - Nucana; Tesaro
 
Alan Anthoney
Consulting or Advisory Role - Novartis (Inst); Ono Pharmaceutical (Inst)
 
Ines Verdon
Employment - Sierra Oncology
Stock and Other Ownership Interests - Gilead Sciences; Sierra Oncology
 
Robert Hugh Jones
Travel, Accommodations, Expenses - Merck